Sign Out
Concurrent use of fenofibric acid and colchicine, simvastatin, atorvastatin, pitavastatin, rosuvastatin, pravastatin or fluvastatin may result in an increased risk of myopathy, including rhabdomyolysis.
Concurrent use of fenofibrate and anticoagulants may result in enhanced anticoagulant effect.
Concurrent use of fenofibrate and rosiglitazone may result in paradoxical decrease in HDL-C.
Concurrent use of fenofibrate and ezetimibe may result in increased ezetimibe concentrations and an increased risk of cholelithiasis.
Concurrent use of fenofibrate and mycophenolate may result in an increased risk of neutropenia.
Concurrent use of fenofibrate and glimepiride may result in increased glimepiride exposure and increased blood glucose lowering effect and risk of hypoglycemia.
Concurrent use of fenofibric acid and cholestyramine may result in decreased fenofibric acid effectiveness.
Concurrent use of fibrates and insulin may result in increased risk of hypoglycemia.
Concurrent use of fenofibric acid and cyclosporine may result in increased risk of renal function deterioration.
Continue with Google